BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Porton Advanced Secures China Commercial Manufacturing Licence for Cell and Gene Therapy CDMO Services

Porton Advanced Solutions Ltd. ("Porton Advanced") has officially been granted a Drug Manufacturing License (Class C) by the National Medical Products Admi...

August 07, 2026 | News

Alteogen Signs Up to $365 Million Hybrozyme Licensing Deal for Subcutaneous Biologic

Alteogen grants exclusive rights to develop and commercialize a subcutaneous biologic product using Hybrozyme™-based hyaluronidase ALT-B4 Alteogen...

August 07, 2026 | News

Adneuris Licenses Cebranopadol Rights to Maruishi for Japan and South Korea

Agreement Grants Maruishi Rights for the Development and Commercialization of Cebranopadol for Pain in Japan and South Korea, Marking Adneuris' Second Ex...

August 07, 2026 | News

Biocon Launches Interchangeable YESAFILI Biosimilar to EYLEA in the U.S.

Yesafili™ (aflibercept-jbvf) now available in the United States as an U.S. FDA-approved interchangeable biosimilar to EYLEA 2 mg Potential ...

August 06, 2026 | News

Forlong Biotechnology Completes Pivotal FL115 Manufacturing Milestone Ahead of Phase III NMIBC Trial

Forlong Biotechnology, a clinical-stage biotech company focused on developing transformative cytokine therapies for patients with severe unmet needs, today...

August 06, 2026 | News

10 Bioprocessing Bottlenecks and How APAC Plants Are Clearing Them

How this list was built Ten bottlenecks were identified from facility interviews, technical sessions at regional bioprocessing conferences and pub...

August 05, 2026 | Analysis

Vaxcellbio Partners with Myellama to Advance Next-Generation NK Cell Therapy for Multiple Myeloma

Vaxcellbio (CEO Je-Jung Lee, MD, PhD), a leading immuno-oncology company, announced today that it has signed a strategic Memorandum of Understanding ...

August 05, 2026 | News

MARS Bioimaging Secures First Clinical Sale of Portable Photon-Counting CT System

Christchurch-based Reform Radiology becomes inaugural clinical customer as New Zealand-developed photon-counting CT technology enters routine clinical&nb...

August 05, 2026 | News

GlycoNex Doses First Patient in Phase I Trial of Novel Glycan-Targeting ADC GNX1021

GlycoNex Inc. announced that the first patient has been successfully dosed in the First-in-Human (FIH) Phase I clinical trial of GNX1021, the Company's nov...

August 04, 2026 | News

Fresenius Kabi's Vedolizumab Biosimilar Clears FDA and EMA Review Milestone

U.S. FDA and EMA acceptance for review of Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, of intraveno...

August 04, 2026 | News

Polpharma Biologics' Vedolizumab Biosimilar Accepted for FDA and EMA Review

Polpharma Biologics International AG announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for r...

August 04, 2026 | News

Advancing Freeze-to-Store Workflows for the Next Era of Biopharmaceutical Manufacturing

As biologics, biosimilars, and advanced cell and gene therapies continue to reshape the Asia-Pacific biopharmaceutical landscape, manufac...

August 03, 2026 | Expert Insight

NIPRO Secures U.S. FDA Clearance for ELISIO-HX Dialyzer to Expand Advanced Hemodialysis Access

New medium-cutoff Dialyzer with a Super High-flux membrane brings NIPRO's approach to expanded hemodialysis to United States healthcare providers. N...

August 03, 2026 | News

CellOrigin Advances In Vivo Cell Therapy Pipeline with ASCO Data and Walvax Partnership

CellOrigin, a biotechnology company focused on next-generation in vivo and in vitro cell therapy technologies, has announced two major progresses in b...

August 03, 2026 | News

Stay Connected